Loading…
Loading the latest PSX data…
Loading the latest PSX data…
Abbott Laboratories (Pakistan) Limited (ABOT), GlaxoSmithKline Pakistan Limited (GLAXO), Haleon Pakistan Limited (HALEON): performance, valuation, growth, risk and danioPSX score, side by side.
Add a stock
Growth of Rs 100 from 2025-11-12
Daily closes from PSX end-of-day files, adjusted for bonus shares, right issues and splits (not for cash dividends). KSE-100: official closes where available, otherwise rebuilt from its constituents.
| Measure | ABOTPharmaceuticals | GLAXOPharmaceuticals | HALEONPharmaceuticals |
|---|---|---|---|
| danioPSX score | 81 | 87 | 67 |
| Price and size | |||
| Price | Rs 1,005.70 | Rs 333.18 | Rs 681.77 |
| Today | +0.18% | −1.89% | −1.15% |
| Market cap | Rs 98.5bn | Rs 106.1bn | Rs 79.8bn |
| Traded per day | Rs 15m | Rs 51m | Rs 20m |
| Valuation and dividends | |||
| P/E | 10.6 | 9.7 | 12.3 |
| Dividend yield | 4.4% | 6.1% | 3.6% |
| EPS (last year) | Rs 81.37 | Rs 31.48 | Rs 54.45 |
| Business | |||
| EPS growth | +52.2% | +53.4% | +39.2% |
| Sales growth | +10.6% | +7.7% | +15.9% |
| Net margin | 10.6% | 15.2% | 14.8% |
| Returns | |||
| 1 month | +6.5% | +6.6% | −0.4% |
| 3 months | +12.1% | −2.9% | −6.7% |
| 1 year | −7.6% | −15.4% | −16.6% |
| vs KSE-100, 1 year | -18.5 pts | -26.3 pts | -27.5 pts |
| Trend and risk | |||
| 52-week position | 41% | 24% | 9% |
| RSI 14 | 67 | 57 | 50 |
| RS rank | 68 | 39 | 29 |
| Volatility | 30% | 34% | 30% |
| Beta | 0.77 | 1.06 | 0.86 |
| danioPSX score | |||
| Value | 61 | 69 | 46 |
| Quality | 74 | 81 | 79 |
| Dividend | 34 | 64 | 45 |
| Momentum | 61 | 34 | 26 |
| Safety | 76 | 80 | 78 |
| Shariah-compliant | Yes | Yes | Yes |
Bold marks the best value in each row where higher (or, for P/E and volatility, lower) is clearly better.
A comparison of published numbers, not a recommendation. Share this page: the address holds the stocks. Find more stocks with the screener